Immune checkpoint inhibitors demonstrated varying degrees of activity in advanced gastric and esophageal cancers, according to preliminary clinical studies reported at the 2016 Gastrointestinal Cancers Symposium. The objective response rates ranged from 9% to 30% with 3 different PD-1 or PD-1 ligand 1 (PD-L1) inhibitors. The safety profiles were consistent with previous studies of checkpoint inhibitors.
The advantages of treatment at a high-volume center extended to adjuvant therapy in patients with resected pancreatic cancer, according to a study reported by Margaret T. Mandelson, PhD, MPH, Floyd and Dolores Jones Cancer Institute, Virginia Mason Medical Center, Seattle, WA, at the 2016 Gastrointestinal Cancers Symposium.
Results 1 - 3 of 3